
LONDON--The share price of British drugmaker AstraZeneca slumped on Monday after it rejected a final takeover bid from U.S. rival Pfizer worth US$117 billion.

The shares tumbled 13.99 percent to 41.49 pounds in early morning deals on London's FTSE 100 index of leading companies, which was down 0.49 percent at 6,822.25 points.

AstraZeneca on Monday rejected a final takeover bid from Pfizer that was pitched at 55 pounds per share, valuing the British firm at 69 billion pounds.

Pfizer had made an improved and final offer on Sunday, but warned that it would not proceed without a recommendation from AstraZeneca management.

Submissions are subject to review and edit, although The China Post is under no obligation to monitor your comments. The China Post reserves the right to post or remove any comment for any reason without prior consent.

You hereby grant to The China Post the right to post your submissions in any way we see fit.

The China Post makes no assurances regarding the accuracy of posted comments. Opinions do not represent the views of The China Post.
